DBV Technologies | DBVT - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
DBV Technologies USD 47.9M 2.2M 2026-03
Galectin Therapeutics USD 11.29M 1.64M 2024-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Incyte USD 973.64M 4.65B 2026-06
Insmed USD 526.79M 20.55M 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
United Therapeutics USD 6.4B 499.2M 2026-06